Rui M. Reis

  • Cancer
  • Genomics
  • Molecular Pathology
  • Biomarkers
  • Cancer Genomics
  • Cancer Cell Biology
  • Translational Oncology

Graduated in Biology at University of Porto, I have been involved in Cancer Research since 1996, at IPATIMUP/Porto (supervision of Prof. Sobrinho-Simões), working on thyroid cancer genetics. In 1997 GABBA Ph.D. fellow (Porto University) and started in 1998 the Ph.D. at IARC/Lyon on molecular pathology of brain tumors (supervision of Prof. Paul Kleihues / Hiroko Ohgaki / Jose M Lopes). In 2002, post-doc at the VUMC/Amsterdam and IPATIMUP (co-supervision of Prof. Gerrit Meijer / Bauke Ylstra / Prof. Fátima Carneiro), on chromosomal aberrations of gastric tumors. In 2003, appointed Assistant Professor at the Medical Faculty, Minho University, Braga, Portugal, and Associate Professor since 2020. In 2010, at Barretos Cancer Hospital/Brazil, coordinator of the Molecular Oncology Research Center and Molecular Diagnostic Laboratory, in 2015 appointed Scientific Director, and from 2018 to 2021 Executive Director of Research and Teaching Institute. In 2021 was appointed Extraordinary Professor, at Pan African Cancer Research Institute, University of Pretoria, South Africa.
My expertise is in cancer biomarkers across distinct tumor types, and applying different methodologies, from SNP, gene mutations, copy number aberrations to gene expression alterations. Experience in international collaborations: COST – Molecular cytogenetics of solid tumors; Marie Curie Conferences -Genome Architecture in Relation to Disease; SIOP, Brain Tumor Committee; IMMENSE consortium; member and local coordinator of NCI-LACRN; Steering Committee of ICGC; Steering Committee of WIN; member and local coordinator of Mutograph (CRUK Grand Challenge); member of COST TRANSPAN.

Scientific Highlights

– Win AK, Dowty GJ, Reece JC, Reis RM, von Knebel Doeberitz, Hopper JL, Haile RW, Macrae FA, Möslein G, Jenkins MA – The International Mismatch Repair Consortium. Variation in the Risk of Colorectal Cancer for Lynch Syndrome: A retrospective family cohort study. Lancet Oncology, 2021 Jul;22(7):1014-1022.
– Pinto F, Costa ÂM, Matsushita MM, Costa S, Silva VA, Lopes CM, Clara CA, Becker AP, Neder L, Hajj GN, da Cunha IW, Jones C, Andrade RP, Reis RM. The T-box transcription factor brachyury behaves as a tumor suppressor in gliomas. Journal of Pathology. 2020 May;251(1):87-99.
– Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Reis RM, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 Apr 5;173(2):371-385.e18.
– Martinho O, Silva-Oliveira R, Cury F, Barbosa AM, Granja S, Evangelista AJ, Marques F, Miranda-Gonçalves V, Carneiro D, de Paula F, Zanon M, Scapulatempo-Neto C, Moreira MA, Baltazar F, Longatto-Filho A, Reis RM. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors. Theranostic, 2017, 7(3): 717-732.
– Mackay A, Burford A, Carvalho A, M, Nandhabalan M, Raman P, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Castel D, Grill J, Hawkins C, Jabado N, Baker S, Pfister S, Jones DT, von Bueren AO, Baudis M, Resnick A, Jones C. Integrated molecular meta-analysis of 1000 paediatric high grade and diffuse intrinsic pontine glioma. Cancer Cell, 2017 Oct 9;32(4):520-537.e5
– Goss PE, Lee BL, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G. Planning cancer control in Latin America and the Caribbean. Lancet Oncology. 2013;14(5):391-436.
– Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM. Association Between Functional EGF+61 Polymorphism and Glioma Risk. Clinical Cancer Research, 2007 1;13(9):2621-6.
– Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, Reis RM. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica, 2005, 109(2): 207-10.

Book Chapter:
Ohgaki H, Biernat W, Reis RM, Hegi M, Kleihues P. Gliosarcoma. In: WHO Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Kleihues P. and Cavenee WK (eds), IARC Press: Lyon, 2000.

– Pfizer/Sociedade de Ciências Médicas de Lisboa Prize in “Research in Oncology Diseases, Prof. Francisco Gentil, 2006, Portugal